Drug Trial Radar · NCT06274528
DORA and LP in Alzheimer's Disease Biomarkers
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
201
Planned (sponsor's estimate)
Start
Mar 11, 2024
Primary completion
Mar 31, 2030
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); Eisai Inc.; National Institute on Aging (NIA)
- First posted
- Feb 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Conditions
- Alzheimer Disease
Interventions
Lemborexant 10 mgDrug
Within FDA approved dose 10 mg; capsule; QD, 6 month duration
Lemborexant 20mgDrug
20 mg; capsule; QD; 6 month duration
PlaceboDrug
0 mg; capsule; QD; 6 month duration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes plasma pT181/T181 ratio of lemborexant 10 and 20 mg compared to PlaceboTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University in St. Louis, School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.